Growth Metrics

Regeneron Pharmaceuticals (REGN) Net Cash Flow (2016 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed Net Cash Flow for 18 consecutive years, with -$152.2 million as the latest value for Q1 2026.

  • For Q1 2026, Net Cash Flow fell 125.22% year-over-year to -$152.2 million; the TTM value through Mar 2026 reached -$121.2 million, down 125.1%, while the annual FY2025 figure was $634.4 million, 355.7% up from the prior year.
  • Net Cash Flow hit -$152.2 million in Q1 2026 for Regeneron Pharmaceuticals, down from $610.9 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $809.4 million in Q1 2023 and bottomed at -$2.0 billion in Q2 2023.
  • Average Net Cash Flow over 5 years is $4.4 million, with a median of $96.2 million recorded in 2022.
  • Year-over-year, Net Cash Flow crashed 4105.47% in 2023 and then surged 573.25% in 2025.
  • Regeneron Pharmaceuticals' Net Cash Flow stood at -$385.4 million in 2022, then skyrocketed by 249.82% to $577.4 million in 2023, then dropped by 17.23% to $477.9 million in 2024, then rose by 27.83% to $610.9 million in 2025, then tumbled by 124.91% to -$152.2 million in 2026.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at -$152.2 million, $610.9 million, and $497.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.